Northern Trust Corp grew its position in CVS Health Corp (NYSE:CVS) by 5.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 15,618,081 shares of the pharmacy operator’s stock after acquiring an additional 807,639 shares during the period. Northern Trust Corp owned 1.53% of CVS Health worth $1,256,631,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Jackson Grant Investment Advisers Inc. raised its position in CVS Health by 0.6% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock worth $232,000 after purchasing an additional 18 shares during the last quarter. Keel Point LLC raised its position in CVS Health by 0.7% during the 1st quarter. Keel Point LLC now owns 3,296 shares of the pharmacy operator’s stock worth $259,000 after purchasing an additional 22 shares during the last quarter. First City Capital Management Inc. raised its position in CVS Health by 0.3% during the 1st quarter. First City Capital Management Inc. now owns 12,771 shares of the pharmacy operator’s stock worth $1,003,000 after purchasing an additional 40 shares during the last quarter. Elefante Mark B raised its position in CVS Health by 0.7% during the 2nd quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock worth $515,000 after purchasing an additional 45 shares during the last quarter. Finally, Traynor Capital Management Inc. raised its position in CVS Health by 1.3% during the 2nd quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock worth $290,000 after purchasing an additional 48 shares during the last quarter. Institutional investors own 82.24% of the company’s stock.
CVS has been the subject of a number of recent analyst reports. Robert W. Baird reiterated a “hold” rating and set a $77.00 price target on shares of CVS Health in a report on Friday, October 27th. Needham & Company LLC upgraded CVS Health from a “hold” rating to a “buy” rating and increased their price target for the stock from $69.02 to $79.00 in a report on Friday, November 10th. Mizuho set a $90.00 price target on CVS Health and gave the stock a “buy” rating in a report on Tuesday, October 24th. BidaskClub downgraded CVS Health from a “hold” rating to a “sell” rating in a report on Friday, August 25th. Finally, Loop Capital initiated coverage on CVS Health in a report on Thursday, August 24th. They set a “hold” rating and a $83.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. CVS Health currently has an average rating of “Buy” and an average target price of $86.24.
CVS Health (NYSE:CVS) last issued its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the business posted $1.64 EPS. analysts anticipate that CVS Health Corp will post 5.9 earnings per share for the current year.
In other CVS Health news, CFO David M. Denton sold 237,078 shares of CVS Health stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the completion of the transaction, the chief financial officer now owns 141,096 shares in the company, valued at approximately $11,238,296.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas M. Moriarty sold 90,267 shares of CVS Health stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.61, for a total value of $7,186,155.87. Following the transaction, the executive vice president now owns 70,102 shares of the company’s stock, valued at approximately $5,580,820.22. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 714,125 shares of company stock valued at $58,119,381. 0.61% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Northern Trust Corp Increases Stake in CVS Health Corp (CVS)” was published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://weekherald.com/2017/12/04/northern-trust-corp-increases-stake-in-cvs-health-corp-cvs.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.